ASX Announcement 30 October 2026 Appendix 4C – September 2026 Quarterly Activities Report Highlights • Clinical validation completed for BREASTESTplus™ 2 in women aged 30 years+ across all breast densities; launch targeted for November 2026 and accreditation and operational activities...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- GSS: Response to Media Speculation & BCAL letter to GSS
- BREASTESTplus 2 clinically validated
- BCAL Introduces Avantect Multi-Cancer Early Detection Test
- Appendix 4E and Annual Report to shareholders
- BCAL Takes Interest in Genetic Signatures to 18.46%
